Veerle H Decalf1, Anja M J Huion2, Dries F Benoit3, Marie-Astrid Denys4, Mirko Petrovic5, Karel C M M Everaert4. 1. Department of Medical Sciences, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium. veerle.decalf@uzgent.be. 2. Department Education, Health and Social work, University College Ghent, Keramiekstraat 80, 9000, Ghent, Belgium. 3. Department of Marketing, Ghent University, Tweekerkenstraat 2, 9000, Ghent, Belgium. 4. Department of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. 5. Department of Geriatrics, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Abstract
INTRODUCTION: Understanding the importance older people attribute to the different side effects associated with oral antimuscarinic treatments for overactive bladder (OAB) could help inform prescribers, healthcare policy makers and the drug industry. OBJECTIVE: Our objective was to quantify the importance of the most prevalent cognitive and side effects of oral antimuscarinic treatments for OAB in older people. METHODS: We conducted a discrete-choice experiment (DCE) with the assistance of an interviewer with community-dwelling and hospitalized older people aged >65 years. The DCE involved two hypothetical drugs for imaginary OAB, with three levels of four side effects for each drug, and the International Consultation on Incontinence Questionnaire-Overactive Bladder and EuroQol 5-Dimensions (EQ-5D) questionnaire were also administered. Data were analysed using a conditional logit model. RESULTS: In total, 276 older people participated in the study. The median age was 75 years (interquartile range [IQR] 69-80), 63% were women and 21% had OAB syndrome. The most unwanted side effect in the choice of antimuscarinics for OAB was severe cognitive effects, followed by severe constipation, severe blurred vision, severe dry mouth, moderate cognitive effects and moderate constipation. Severe cognitive effects were at least 1.7 times as important as severe constipation. Exploratory subgroup analysis showed that none of the attributes was found to be significant in people who scored as anxious or depressed on the EQ-5D, and preferences about cognitive effects, constipation and blurred vision were equal in people with and without OAB. CONCLUSION: Older people attribute more importance to loss of cognitive function as a possible side effect of antimuscarinic treatment than to the three most prevalent possible side effects of this treatment.
INTRODUCTION: Understanding the importance older people attribute to the different side effects associated with oral antimuscarinic treatments for overactive bladder (OAB) could help inform prescribers, healthcare policy makers and the drug industry. OBJECTIVE: Our objective was to quantify the importance of the most prevalent cognitive and side effects of oral antimuscarinic treatments for OAB in older people. METHODS: We conducted a discrete-choice experiment (DCE) with the assistance of an interviewer with community-dwelling and hospitalized older people aged >65 years. The DCE involved two hypothetical drugs for imaginary OAB, with three levels of four side effects for each drug, and the International Consultation on Incontinence Questionnaire-Overactive Bladder and EuroQol 5-Dimensions (EQ-5D) questionnaire were also administered. Data were analysed using a conditional logit model. RESULTS: In total, 276 older people participated in the study. The median age was 75 years (interquartile range [IQR] 69-80), 63% were women and 21% had OAB syndrome. The most unwanted side effect in the choice of antimuscarinics for OAB was severe cognitive effects, followed by severe constipation, severe blurred vision, severe dry mouth, moderate cognitive effects and moderate constipation. Severe cognitive effects were at least 1.7 times as important as severe constipation. Exploratory subgroup analysis showed that none of the attributes was found to be significant in people who scored as anxious or depressed on the EQ-5D, and preferences about cognitive effects, constipation and blurred vision were equal in people with and without OAB. CONCLUSION: Older people attribute more importance to loss of cognitive function as a possible side effect of antimuscarinic treatment than to the three most prevalent possible side effects of this treatment.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Deborah Marshall; John F P Bridges; Brett Hauber; Ruthanne Cameron; Lauren Donnalley; Ken Fyie; F Reed Johnson Journal: Patient Date: 2010-12-01 Impact factor: 3.883
Authors: Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams Journal: Eur Urol Date: 2006-10-02 Impact factor: 20.096
Authors: M Heisen; S A Baeten; B G Verheggen; M Stoelzel; Z Hakimi; A Ridder; R van Maanen; E A Stolk Journal: Curr Med Res Opin Date: 2016-02-12 Impact factor: 2.580
Authors: Chris C Sexton; Karin S Coyne; Christine Thompson; Tamara Bavendam; Chieh-I Chen; Alayne Markland Journal: J Am Geriatr Soc Date: 2011-06-30 Impact factor: 5.562
Authors: Annette Eidam; Anja Roth; André Lacroix; Sabine Goisser; Hanna M Seidling; Walter E Haefeli; Jürgen M Bauer Journal: Patient Prefer Adherence Date: 2020-03-04 Impact factor: 2.711